The Hong Kong-listed company, known for its focus on metabolic disease therapeutics, expects the move to broaden its investor base and strengthen its market standing. Management views this integration into the cross-border trading mechanism as a validation of its investment profile and long-term growth strategy. By simplifying the purchase process for mainland market participants, Ascletis aims to increase the trading volume of its ordinary shares while supporting its ongoing innovation in drug development.

Ascletis currently maintains a diverse portfolio of drug candidates, including GLP-1R agonists for weight management and diabetes. The company leverages proprietary technologies, such as its Artificial Intelligence-assisted Structure-Based Drug Discovery platform, to advance its pipeline. Through the Stock Connect, the firm joins a select group of companies accessible to mainland capital, potentially providing the financial flexibility needed to sustain its research-intensive operations.